At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you. Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" or “@brassring.com” email accounts.
Biogen’s commitment to improving the lives of patients guides every aspect of our manufacturing operations. We take our responsibility of making and delivering quality medicine very seriously. We have been successfully manufacturing large molecule therapies for over two decades. In recent years we have extended our expertise into the production of small molecule therapies and have fully integrated an oral solid dose facility into our manufacturing infrastructure.
We attribute our success to excellence in several key areas. Our process development team continually advances our understanding of the biology and the process technology that are both critical to improving our capabilities and output. Our advanced engineering teams ensure that our manufacturing plants are state of the art with cutting-edge technologies to meet demand for our existing therapies, clinical trials and opportunities in biosimilars. Our world-class manufacturing teams are the key to efficient and reliable operation of these assets. Thorough business continuity planning provides redundancy on a global level to ensure product availability. In addition, these teams create systems that minimize our impact on the environment by limiting waste and using resources efficiently.
Our quality team manages compliance and supervises consistent and dependable production of our therapies, while our supply chain group makes sure that we are able to get our therapies to patients, when and where they need them. The combination of these skills and focuses enable us to manufacture and supply medicines to patients in more than 90 countries.
In the coming years we expect to substantially increase our production capabilities by focusing on innovation that allows us to scale in advance of new pipeline products. Today we can rapidly increase production of small molecules and biologics, providing flexibility and protection to our supply chain.
Biogen operates several manufacturing facilities around the world. Together, they total 198,000 liters of bioreactor capacity, one of the largest among biotech companies worldwide.
Research Triangle Park in North Carolina
In 2013, RTP won the Facility of the Year award in the facility integration category from the International Society for Pharmaceutical Engineering, Pharmaceutical Processing magazine and INTERPHEX, one of the industry’s leading trade events. With this facility we introduced an innovative process for early-stage clinical products. Single-use technology in a closed system replaces the traditional stainless-steel systems. This increases flexibility and speed of supplying drugs for clinical studies, and reduces the environmental impacts of the manufacturing process.
Hillerød, Denmark
Biogen’s Hillerød campus brings together a complete range of expertise, capabilities and technologies to reliably manufacture advanced biologics. Our large-scale manufacturing facility manufactures innovative therapies and biosimilars for clinical and commercial use. Our medical device assembly, labeling and packing prepares medicines for delivery to more than 90 countries. The campus is the single-largest foreign greenfield investment in Denmark.
Solothurn, Switzerland
Construction on this next-generation biologics manufacturing facility began in 2016 and is expected to be completed in 2019. The Solothurn facility will produce up to ten metric tons of antibody per year, helping us provide meaningful therapies to patients with serious medical conditions around the globe.
You are now leaving Biogen’s corporate website.
We encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from Biogen’s standards.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.
